

June 9, 2015



## Ceapro Announces Election of Directors at 2015 Shareholders' Meeting

EDMONTON, ALBERTA -- (Marketwired) -- 06/09/15 -- [Ceapro Inc. \(TSX VENTURE:CZO\)](#) ("**Ceapro**" or the "**Company**"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 3, 2015.

All other matters at the Shareholders' meeting, namely the appointment of Auditors and the Re-approval and Ratification of the Company's Stock Options Plan, were also approved by shareholders.

At a Board of Directors meeting subsequent to the Annual and Special Meeting the following appointments were made:

- Glenn Rourke, Chair of the Board and Chair of the Audit Committee
- Gilles Gagnon, President and Chief Executive Officer
- Stacy Prefontaine, Chief Financial Officer and Corporate Secretary

### ***About Ceapro Inc.***

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at [www.ceapro.com](http://www.ceapro.com).

***Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

Source:

Ceapro Inc.

[www.ceapro.com](http://www.ceapro.com)

INVESTOR AND MEDIA CONTACT:

Jenene Thomas

Jenene Thomas Communications, LLC  
Investor Relations and Corporate Communications Advisor  
(US): 908-938-1475  
[jenene@jenenethomascommunications.com](mailto:jenene@jenenethomascommunications.com)

Source: Ceapro Inc.